President Trump highlights child’s hearing restored by Regeneron gene therapy at White House
Updated
Updated · Fox News · Apr 24
President Trump highlights child’s hearing restored by Regeneron gene therapy at White House
7 articles · Updated · Fox News · Apr 24
At the Oval Office event, Trump introduced 2-year-old Travis Smith and his mother Sierra, sharing their experience with Regeneron's Otarmeni gene therapy, which restored Travis’s hearing after he was born deaf.
Regeneron announced the FDA’s accelerated approval of Otarmeni and committed to providing the therapy free to clinically eligible U.S. patients, though surgery and administration costs may still apply.
Trump also stated that 17 major pharmaceutical companies, covering 80% of the branded drug market, have agreed to offer prescription drugs to Americans at the lowest global prices.
Is Regeneron's free gene therapy a generous gift or a clever strategy to sidestep the larger debate on drug pricing?
Will 'most favored nation' drug pricing deals actually lower out-of-pocket costs for the average American family?
With the Otarmeni therapy being free, what are the hidden surgical and hospital costs families will still face?
After curing this rare form of deafness, what is the next major sensory function gene therapy aims to restore?
How does gene therapy's ability to perceive music compare to that of traditional cochlear implants for deaf children?
This therapy restores hearing, but how might it impact the established Deaf culture and identity for future generations?